A Phase II Trial of Pemetrexed in Advanced Breast Cancer: Clinical Response and Association with Molecular Target Expression
Open Access
- 1 February 2006
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 12 (3), 832-838
- https://doi.org/10.1158/1078-0432.ccr-05-0295
Abstract
Purpose: This phase II trial of pemetrexed explored potential correlations between treatment outcome (antitumor activity) and molecular target expression.Keywords
This publication has 25 references indexed in Scilit:
- Phase II Study of Pemetrexed in Patients Pretreated with an Anthracycline, a Taxane, and Capecitabine for Advanced Breast CancerClinical Breast Cancer, 2005
- Can Patients' Likelihood of Benefiting from Primary Chemotherapy for Breast Cancer Be Predicted Before Commencement of Treatment?Breast Cancer Research and Treatment, 2004
- Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast CancerJournal of Clinical Oncology, 2004
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With ChemotherapyJournal of Clinical Oncology, 2004
- Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural MesotheliomaJournal of Clinical Oncology, 2003
- Loss of folylpoly‐γ‐glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation‐dependent novel antifolates in multiple human leukemia sublinesInternational Journal of Cancer, 2002
- Assessing TP53 status in human tumours to evaluate clinical outcomeNature Reviews Cancer, 2001
- Resistance to Tomudex (ZD1694): Multifactorial in human breast and colon carcinoma cell linesBiochemical Pharmacology, 1996
- Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracilBiochemical Pharmacology, 1995
- Amplification and organization of dihydrofolate reductase genes in a human leukemic cell line, K-562, resistant to methotrexateBiochemistry, 1983